# Methyl-CpG-binding protein 2 reads histone methylation via an aromatic cage to regulate gene expression and chromatin association

**Authors:** Jyotirmayee Padhan, Babu Sudhamalla

PMC · DOI: 10.1016/j.jbc.2025.111115 · The Journal of Biological Chemistry · 2025-12-29

## TL;DR

This study shows that MeCP2, a protein linked to neurological disorders, can bind to histone methylation marks, helping regulate gene expression and chromatin structure.

## Contribution

The study identifies an aromatic cage in MeCP2 that binds histone methylation marks, revealing a new mechanism for its gene regulatory function.

## Key findings

- MeCP2 binds to H3K27me3 via an aromatic cage formed by W104, F132, Y141, F142, and F155.
- Mutation of the aromatic cage residue W104A reduces MeCP2 chromatin occupancy and gene regulation.
- MeCP2 localizes to histone methylation marks like H3K4me3 and H3K27me3, influencing cancer-related pathways.

## Abstract

Methyl-CpG binding protein 2 (MeCP2) is a DNA methylation reader, which is highly expressed in the central nervous system. Loss-of-function mutation of MeCP2, which impairs DNA binding, causes Rett syndrome, while gain of MeCP2 function causes MeCP2 duplication syndrome. MeCP2 functions as both a transcription activator and a repressor, but its full range of activity remains largely unknown. A recent study suggests that beyond DNA binding, MBD domain of MeCP2 also interacts with methylated lysine residues on histone H3 tail. In this study, we aimed to characterize the methyllysine-binding pocket of MeCP2-MBD. Structural analysis reveals the presence of an aromatic cage formed by five residues, namely, W104, F132, Y141, F142, and F155, where the trimethyllysine of H3K27me3 binds, as confirmed in docking studies. Alanine substitution of these residues abolished the binding of MeCP2-MBD with its reported ligand H3K27me3 in ITC and pull-down experiments. Genomic analysis of publicly available ChIP-seq data reveals that MeCP2 localizes with canonical histone methylation marks like H3K4me3, H3K9me3, H3K27me3, and H4K20me3 and regulates critical biological and cancer-related pathways. Promoters of MeCP2-regulated genes show a signature of H3K4me3 and H3K27me3. At the genomic level, mutation of aromatic cage residue W104A significantly reduced chromatin occupancy of MeCP2 as demonstrated by ChIP-qPCR experiments. Furthermore, our qRT-PCR experiment shows that this aromatic cage-dependent binding is necessary for regulating the expression of MeCP2 target genes. Overall, our study establishes MeCP2 as a histone methylation reader and highlights the functional significance of its histone binding capacity in chromatin association and gene regulation.

## Linked entities

- **Genes:** MECP2 (methyl-CpG binding protein 2) [NCBI Gene 4204]
- **Proteins:** MECP2 (methyl-CpG binding protein 2)
- **Diseases:** Rett syndrome (MONDO:0010726), MeCP2 duplication syndrome (MONDO:0010283)

## Full-text entities

- **Genes:** MECP2 (methyl-CpG binding protein 2) [NCBI Gene 4204] {aka AUTSX3, MRX16, MRX79, MRXS13, MRXSL, PPMX}
- **Diseases:** cancer (MESH:D009369), Rett syndrome (MESH:D015518)
- **Chemicals:** H3K27me3 (-), trimethyllysine (MESH:C003712)
- **Mutations:** W104A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12857291/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12857291/full.md

## References

87 references — full list in the complete paper: https://tomesphere.com/paper/PMC12857291/full.md

---
Source: https://tomesphere.com/paper/PMC12857291